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Abst rac t
Background and purpose: The Montreal Cognitive Assess-
ment (MoCA) test is a brief cognitive screening tool with
high sensitivity and specificity for detecting mild cognitive
impairment (MCI). The aim of this study was to evaluate the
usefulness of MoCA and compare it with the Mini-Mental
State Examination (MMSE) in the early detection of cogni-
tive decline in MCI.
Material and methods: A group of 115 subjects (36 meeting
DSM-IV criteria for Alzheimer disease (AD) [Clinical
Dementia Rating (CDR) = 1], 42 meeting Petersen’s crite-
ria for MCI [CDR = 0.5], and 37 cognitively intact con-
trols [CDR = 0]) was recruited for the study in the univer-
sity-based Alzheimer out-patient clinic. All participants
underwent general medical, neurological, and psychiatric
examinations. The MoCA, the MMSE, CDR and the short
(15-item) version of the Geriatric Depression Scale were also
applied.
Results: Both MCI and AD groups exhibited impaired per-
formance on MoCA compared to controls. Polish versions
of the MMSE and MoCA tests were comparable in dis-
criminating mild dementia from both MCI and control
groups. The Polish version of the MoCA test performed mar-
ginally better than MMSE in discriminating MCI from con-
trols. We propose to use the MoCA test to screen for MCI
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St reszczenie
Wstêp i cel pracy: Montrealski Test do Oceny Stanu Poznaw-
czego (Montreal Cognitive Assessment – MoCA) jest narzêdziem
do przesiewowej oceny stanu poznawczego i cechuje siê du¿¹
czu³oœci¹ oraz swoistoœci¹ w wykrywaniu ³agodnych zaburzeñ
poznawczych (mild cognitive impairment – MCI). Celem pra-
cy by³a ocena przydatnoœci testu MoCA oraz porównanie 
z Krótk¹ Skal¹ Oceny Stanu Psychicznego (Mini-Mental 
State Examination – MMSE) we wczesnym wykrywaniu
³agodnych zaburzeñ poznawczych.
Materia³ i metody: Przeprowadzono badanie z u¿yciem pol-
skiej wersji testu w grupie 115 osób, w tym 36 chorych na
chorobê Alzheimera o nasileniu ³agodnym wg DSM-IV [Cli-
nical Dementia Rating (CDR) = 1], 42 pacjentów z MCI
(CDR = 0,5) oraz 37 zdrowych osób w grupie kontrolnej
(CDR = 0) – pacjentów poradni przyklinicznej o profilu
psychogeriatrycznym. U wszystkich uczestników projektu
przeprowadzono ocenê ogólnego stanu somatycznego, bada-
nie neurologiczne i psychiatryczne oraz dokonano oceny
z u¿yciem MoCA, MMSE, CDR oraz 15-punktowej wer-
sji Geriatrycznej Skali Depresji (Geriatric Depression Scale).
Wyniki: Zarówno pacjenci z MCI, jak i z chorob¹ Alzhei -
mera wykonali test MoCA gorzej w porównaniu z osobami
z grupy kontrolnej. W badanej populacji testy MMSE
i MoCA okaza³y siê porównywalne w odró¿nianiu otêpienia
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Introduction
A dramatic increase in the incidence of Alzheimer
disease (AD) in the near future is predicted. Therefo-
re, there is a growing interest in identifying adults at
high risk for developing cognitive decline. The concept
of a transitional state between normal aging and AD or
other dementia subtypes has been present in the litera-
ture for many years [1,2]. Mild cognitive impairment
(MCI) is a condition characterized by an acquired
cognitive impairment without significant functional 
decline in the activities of daily living, constituting an
intermediate stage between normal aging and demen-
tia. Mild cognitive impairment is a heterogeneous cli-
nical syndrome for which no DSM (Diagnostic and Sta-
tistical Manual of Mental Disorders) Fourth Edition
(DSM-IV) or ICD (International Statistical Classifi-
cation of Diseases and Related Health Problems) crite-
ria have yet been established. The criteria by Petersen 
et al. are currently the most frequently applied in every-
day clinical practice [3,4], but revisions and other pro-
positions also exist [5,6]. The diagnosis of MCI requi -
res considerable clinical judgment. Neuropsychological
testing with standardized tests is often used to assess and
characterize MCI patients, but many clinicians lack easy
and timely access to such assessments or to tertiary care
memory clinics. For that reason, there is a need for sen-
sitive but user-friendly cognitive screening tests for cli-
ni cians, such as the Montreal Cognitive Assessment
(MoCA) test [7]. Moreover, clinical and neuropsy-
chological studies are needed that can better characteri-
ze which screening methods are the most efficacious in
the process of diagnosing MCI cases.
The Mini-Mental State Examination (MMSE) was
published in 1975 as a practical means of evaluating
cognitive functions [8]. The Mini-Mental State Exa-
mination has been considered the ‘gold standard’ and is
currently one of the most widely used tools for the asse -
ssment of cognitive impairment in both clinical practi-
ce and research [9]. The Mini-Mental State Exami-
nation was suggested as a useful MCI screening tool in
the guidelines of the American Academy of Neurology
[10], but it may not adequately capture early cognitive
deficits associated with dementia [8]. Moreover, a num-
ber of issues were raised regarding the sensitivity of some
MMSE subtests and the impact of age, education, ethnic
differences and gender on the final score [11-13].
There is a need for a tool detecting individuals who
will subsequently develop AD and now score within the
normal range on the MMSE. The Mini-Mental State
Examination and other popular dementia screening tests
lack sensitivity owing to ceiling effects, especially in high-
ly educated subjects [14]. Interpretation of the MMSE
score is further hampered by the need for complicated
age and education adjustments [15].
A growing number of novel cognitive screening tests
are being developed. A major focus is on increasing sen-
 sitivity, covering more domains than MMSE, address -
ing frontal/executive functioning, and decreasing suscep-
tibility to cultural and educational biases [16].
Increasing doubts on the applicability of MMSE
for MCI screening resulted in the preparation of alter-
native tools, including the MoCA test. The MoCA test
is a short (usually it can be administered within 10 minu-
tes), one-page, paper-and-pencil screening test [7]. 
The test consists of tasks assessing the following doma-
ins: short-term memory, visuospatial abilities, executive
functions, phonemic fluency, verbal abstraction, atten-
tion, concentration, working memory, language, and,
finally, orientation to time and place. A comparison of
cognitive domains covered by the MMSE and MoCA
is presented in Table 1. 
using an optimal cut-off score of 24 and to screen for demen-
tia using a cut-off score of 19.
Conclusions: The Polish version of the MoCA seems effec-
tive in the detection of deteriorated cognitive performance
and appropriate for differentiating impaired from preserved
cognitive function in a Polish population.
Key words: screening, mild cognitive impairment, Montreal
Cognitive Assessment, MoCA.
o nasileniu ³agodnym od MCI i osób zdrowych. Wykaza -
no minimaln¹ przewagê polskiej wersji testu MoCA nad
MMSE w odró¿nianiu osób z MCI od grupy kontrolnej.
Autorzy proponuj¹ stosowanie testu MoCA jako narzêdzia
przesiewowego do wykrywania zaburzeñ poznawczych i sto-
sowanie punktu odciêcia na poziomie 24 punktów dla ³agod-
nych zaburzeñ poznawczych oraz 19 punktów dla otêpienia.
Wnioski: Wykazano przydatnoœæ polskiej wersji testu MoCA
w wykrywaniu deficytów poznawczych i odró¿nianiu osób
z MCI od osób zdrowych w polskiej populacji.
S³owa kluczowe: badanie przesiewowe, ³agodne zaburzenia
poznawcze, Montrealski Test do Oceny Stanu Poznawczego,
MoCA.
MoCA test in screening for cognitive impairment
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The total possible score in MoCA is 30; a score 
of 26 or above is considered normal. A score below 
26 points in subjects demonstrating no functional impa-
irment is suggestive of MCI. The early stage of demen-
tia is indicated by a score below 26 with concomitant
functional impairment. One extra point is added in cases
with less than 12 years of formal education.
Montreal Cognitive Assessment is a cognitive scre-
ening tool with high sensitivity and specificity for detect -
ing MCI in subjects performing within the normal ran-
ge on the MMSE [7]. It is argued that most patients
meeting clinical criteria for MCI score above 26 points
on the MMSE, which is also the ‘healthy’ range for
cognitively intact elderly. The Montreal Cognitive Ass -
essment might be particularly useful in this context, as
it turned out to be more sensitive than the MMSE for
the detection of MCI and mild AD in the general popu-
lation. An MoCA score below 26 was considered the
optimal cut-off threshold for the diagnosis of cognitive
impairment even in individuals performing well on 
the MMSE. Moreover, compared to MMSE, MoCA
covers a broader range of cognitive domains and can be
useful in evaluating cognitive decline of various aetio-
logies [17-21].
The origins of the test, content details and scoring
rules were described by Nasreddine and colleagues [7].
Initially, only French and English versions of the MoCA
were prepared and evaluated. Currently, the MoCA is
being translated and validated in several other langu-
ages [22-24].
The Polish version of the MoCA test was prepared
in the Department of Old Age Psychiatry and Psycho-
tic Disorders, Medical University of Lodz [25]. En -
glish, Polish and versions in other languages are availa-
ble at www.mocatest.org.
The objective of this study was to evaluate the use-
fulness of the MoCA versus the MMSE in the early
detection of cognitive decline in MCI.
Material and methods
The study was conducted in a university-based AD
out-patient clinic. In the pilot study, the Polish version
Cognitive function/item MMSE (No. of points/task) MoCA (No. of points/task)
Orientation 10 items (10) 6 items (6)
Memory learning learning of 3 words (1 trial allowed) (3) learning of 5 words 
(2 trials allowed) (no points)
delayed recall 3 words (3) 5 words (5)
cued recall (optional) not present 5 words (no points)
recognition (optional) 5 words (no points)
Naming 2 objects (2) 3 pictures (3)
Visuospatial functions copy of pentagons (1) copy of cube (1)
clock drawing (3)
Comprehension 3-stage command (3) not present
Attention serial 7 subtracting (5) forward Digit Span (1)
backward Digit Span (1)
serial 7 subtracting (3)
Vigilance not present tapping with hand at letter A (1)
Language repetition of sentence (1) repetition of 2 sentences (2)
letter fluency (1)
Reading sentence (1) not present
Abstract thinking not present similarities (2)
Writing patient’s sentence (1) not present 
Alternating Trail Making not present 1 trial (1)
Table 1. Comparison of cognitive functions assessed during Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) examination
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of the MoCA was prepared. In the current study, the
comparative usefulness of the MoCA test versus the
MMSE in the early detection of cognitive decline in
MCI was evaluated.
Written informed consent for the study was obtained
from all subjects before inclusion. The study was appro-
ved by the Ethics Committee of the Medical Universi-
ty of Lodz (RNN/598/07/KB).
Study participants
A group of 115 participants matched for age, gen-
der and years of formal education was recruited for 
the current study and divided into three groups: patients
with mild AD, patients meeting criteria for MCI, and
cognitively intact elderly controls.
The main inclusion criterion was the final CDR 
score: 0 for controls, 0.5 for MCI and 1 for AD cases.
Subjects meeting that criterion were further evaluated
clinically and psychometrically.
The AD group consisted of 36 cases with probable
AD diagnosed according to the DSM-IV criteria [26].
The diagnosis of dementia was based on the clinical and
neuropsychological assessments and given before inc-
lusion in this study. The MoCA test was applied inde-
pendently of the MCI or AD diagnostic process. All
demented subjects had an informant who provided an
adequate clinical history.
The MCI group consisted of 42 elderly participants.
Mild cognitive impairment was diagnosed based on cli-
nical evaluation and previously established criteria [3].
Accordingly, the group comprised subjects with subjec-
tive complaints of gradual memory loss over at least 
6 months reported by the patient or family members.
Individuals demonstrated objective evidence of memo-
ry loss confirmed by the clinician, general preservation
of other cognitive domains and normal level of functio-
ning in activities of daily living. The group of MCI cases
was heterogeneous and consisted of different subtypes
of MCI. The inclusion process was based solely on the
CDR score and general Petersen’s criteria, without spe-
cifically focusing on selecting the amnestic-type MCI
subjects. Nevertheless, the majority of recruited cases
met criteria for amnestic MCI and some could be clas-
sified as mixed MCI. Subjects with other obvious medi-
cal, neurological, or psychiatric causes of memory loss
were excluded. The MCI patients showed no psychia-
tric comorbidity as well.
The control group consisted of 37 healthy elderly
volunteers recruited from the community, without sub-
jective cognitive complaints and normal baseline neu-
ropsychological performance. The control subjects also
underwent a clinical psychiatric examination to exclude
psychiatric comorbidity.
Demographic characteristics of the study participants
are presented in Tables 2 and 3. 
The proportion of women in each group was simi-
lar. The control subjects were significantly younger than
both MCI and AD patients; the latter two groups were
matched for age. Patients with AD were significantly
less educated than both MCI and controls, while MCI
subjects and controls had a comparable level of educa-
tion (p = 0.4).
Due to differences in age and education of study par-
ticipants, linear regression was used to perform adjust-
ment for those variables significantly correlated with
MoCA and/or MMSE scores.
Variable AD MCI Controls ANOVA F (p) Between-group comparisons  
(N = 35) (N = 42) (N = 37) (p values)
AD vs. AD vs. MCI vs.
MCI controls controls
Gender (proportion 0.7 0.8 0.7 NA No difference between the groups
of women)
Age [years]; 76.3 ± 5.8 74.2 ± 6.4 71.4 ± 5.2 6.3 0.29 0.002 0.11
mean ± SD (p = 0.002)
Education [years]; 9.1 ± 3.7 13.4 ± 4.9 14.3 ± 3.1 17.40 0.0002 0.0001 0.62
mean ± SD (p < 0.0001)
Table 2. Demographic characteristics of study participants. Post-hoc testing of between-group comparisons was performed for statistically significant results of analy-
sis of variance (ANOVA)
SD – standard deviation, AD – Alzheimer disease, MCI – mild cognitive impairment, NA – not applicable
MoCA test in screening for cognitive impairment
Neurologia i Neurochirurgia Polska 2012; 46, 2134
Instruments
Montreal Cognitive Assessment (MoCA)
The Polish version of the MoCA was demonstrated
previously [25]. It has officially been approved by the
constructors of the test (available at www.mocatest.org)
and administered during the current study.
The scale was adapted through translation and back
translation to guarantee semantic equivalence. The Po -
lish version of the MoCA is identical to the English ver-
sion except for two sentences used in the repetition task,
having been replaced by Polish equivalents carrying the
same meaning. The second obstacle while preparing 
the Polish adaptation was the need to modify the letter
fluency item. The letter fluency test, called FAS (using
the initial letters F, A and S) is probably the most com-
monly used letter fluency task. Various letters are used
in different languages depending on their relative fre-
quencies; however, normative data are available for these
versions. The standardization of the test is essential as
clinicians may administer many alternate versions when
no normative data exist. For example, letters K, S, P
or M and W are used in Polish but normalization of
these versions in practice is lacking. Moreover, the FAS
fluency test is frequently used for clinical and research
purposes in Poland as well as in many other countries.
Taking that into account we decided to apply the letter
F taken from the original FAS test. Finally, there were
some doubts considering the choice of words for the
learning task. Like the authors of other local versions of
the MoCA, we decided to use the list of words directly
from the English version, translated into Polish. In our
opinion this guarantees the semantic equivalence of the
testing task.
General assessment
All subjects underwent general medical, neurologi-
cal and psychiatric investigations. The testing battery
applied included the MoCA [7,25], MMSE [8],
CDR scale [27], and the short (15-item) version of the
Geriatric Depression Scale (GDS) [28]. The choice of
applied tools was to guarantee diagnostic precision and
correct attribution to study groups.
None of the participating subjects had any signs of
neurological or unstable somatic disease.
Examination procedure 
The first stage comprised the recruitment of cases.
For that purpose, the CDR scale was applied (R.M.).
Subjects meeting the main inclusion criterion (CDR
score, as mentioned above) were further evaluated cli-
nically with the clinical criteria for AD and MCI
(R.M.) and battery of instruments. All participants were
administered the MMSE test, MoCA test, and GDS
(J.M.). The second rater performed general clinical
assessment (R.M.). The tests were administered in the
same order and the same standardized instructions were
given.
Some tasks overlap between the MMSE and MoCA
tests; therefore the MoCA test was performed at the be -
Variable AD MCI Controls ANOVA F (p) Between-group comparisons  
(N = 35) (N = 42) (N = 37) (p values)
AD vs. AD vs. MCI vs.
MCI controls controls
MMSE 23.1 ± 2.4 27.7 ± 1.7 28.9 ± 1.0 39.85 0.0001 0.0001 0.29
[total points]; (p < 0.0001)
mean ± SD
MoCA 15.1 ± 2.6 22.1 ± 3.0 25.1 ± 2.8 57.83 0.0001 0.0001 0.0004
[total points]; (p < 0.0001)
mean ± SD
GDS 3.7 ± 3.1 3.4 ± 2.6 2.4 ± 2.4 2.31 NS NS NS
[total points]; (p = 0.1038)
mean ± SD
Table 3. Clinical characteristics of study participants. Post-hoc testing of between-group comparisons was performed for statistically significant results of analysis 
of variance (ANOVA)
MMSE – Mini-Mental State Examination, MoCA – Montreal Cognitive Assessment, GDS – Geriatric Depression Scale, SD – standard deviation, AD – Alzheimer disease, MCI – mild
cognitive impairment, NS – not significant
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ginning, followed by the MMSE. The orientation 
scores and serial 7s trial score were copied onto 
the MMSE sheet. The serial 7s task acts as a distracter
for the recall of three words. While applying the
MMSE, we decided to perform comprehension tasks
at this point.
Data management and statistical analysis
Continuous variables are presented as means and
standard deviations. To determine differences between
the analysed groups, analysis of variance (ANOVA) with
post-hoc verification using Tukey’s test was performed.
Categorical variables are presented as fractions. Diffe-
rences of such characteristics between the groups were
calculated using Pearson’s chi-square test. The Mini-
Mental State Examination and MoCA raw scores were
adjusted for age and years of education using a linear
regression model. ROC curves were used to compare
the diagnostic performance of MMSE and MoCA in
discriminating dementia from MCI and controls as well
as MCI versus controls. A p-value threshold of 0.05 was
imposed as the statistical significance level for chi-squ-
are tests and ANOVA with the same threshold appli ca-
ble for post-hoc testing. For ROC curves, 95% confiden-
ce intervals not including the value 0.5 were considered
statistically significant.  
Results
The data of 115 subjects were collected for this stu-
dy, including 36 with mild AD dementia (CDR = 1), 
42 with MCI (CDR = 0.5) and 37 controls (CDR = 0).
Both MMSE and MoCA scores were significantly dif-
ferent in all between-the-group comparisons (AD vs. con-
trols, AD vs. MCI, MCI vs. controls; data presented in
Table 3). The GDS scores were comparable in all study
groups (data presented in Table 3).
A pairwise comparison of areas under the ROC
curves was performed to compare the clinical applica-
bility of the MMSE and MoCA tests in separating the
groups. Different cut-off scores were tested and likeli-
hood ratios, sensitivity and specificity were calculated
both for MMSE and MoCA (results are presented in
Tables 4-7).
As MMSE is supposed to be a screening test, it is
much more important not to miss any case of dementia
Test and cut-off Sensitivity Specificity + Likelihood – Likelihood Number needed
score used Ratio Ratio to diagnose
MMSE ≤ 23 40.0 (23.9-57.9) 98.7 (93.1-99.8) 31.6 0.6 2.6
MMSE ≤ 24 48.6 (31.4-66.0) 94.9 (87.5-98.6) 9.6 0.5 2.3
MMSE ≤ 25 60.0 (42.1-76.1) 92.4 (84.2-97.1) 7.9 0.4 1.9
MMSE ≤ 26* 80.0 (63.1-91.5) 77.2 (66.4-85.9) 3.5 0.3 1.7
MMSE ≤ 27 88.6 (73.2-96.7) 62.3 (50.4-72.7) 2.3 0.2 2.0
Table 4. Psychometric characteristics of Mini-Mental State Examination (MMSE) in detecting Alzheimer disease (AD) dementia (N = 36) versus combined groups 
of mild cognitive impairment (MCI) and controls (N = 79). Optimum cut-off based on ROC curve with area under the curve (AUC) 0.86 (95% CI 0.78-0.92) equall ed
26 and is marked with an asterisk
Test and cut-off Sensitivity Specificity + Likelihood – Likelihood Number needed
score used Ratio Ratio to diagnose
MMSE ≤ 24 0.0 (0.0-8.5) 100.0 (90.4-100.0) – 1.0 –
MMSE ≤ 25 14.3 (5.5-28.6) 100.0 (90.4-100.0) – 0.9 7.0
MMSE ≤ 26 28.6 (15.7-44.6) 83.7 (68.0-93.8) 1.8 0.8 8.1
MMSE ≤ 27* 47.6 (32.0-63.6) 72.9 (55.9-86.2) 1.8 0.7 4.9
MMSE ≤ 28 76.2 (60.5-87.9) 40.5 (24.8-57.9) 1.3 0.6 6.0
Table 5. Psychometric characteristics of Mini-Mental State Examination (MMSE) in differentiating patients with mild cognitive impairment (MCI) (N = 42) from con-
trols (N = 37). Optimum cut-off based on ROC curve with area under the curve (AUC) 0.61 (95% CI 0.50-0.72) equalled 27 and is marked with an asterisk
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than to have a false positive result. The best parameters
in terms of likelihood ratios and false negative results
were achieved with a cut-off score of 26 (results are pre-
sented in Table 4). Interestingly, a commonly recom-
mended cut-off score of 24 yielded a highly unaccepta-
ble result of 40% false negatives. Therefore, we propose
a cut-off score of 26 as the best for dementia detection,
with a false negative rate of 20% and a false positive rate
of 23%. 
The Mini-Mental State Examination proved to per-
form poorly in discriminating MCI from healthy con-
trols. Even for MMSE ≤ 27 the rate of false negative
MCI attributions was as high as 52.5%, while using
MMSE ≤ 28 gave an unacceptable 59.5% rate of false
positives (results are presented in Table 5). Thus, MMSE
could not be reliably used in our sample for the detec-
tion of MCI.
The optimal MoCA cut-off score for differentiating
dementia from MCI/controls was 19, providing deci-
sion-making level likelihood ratios (results are presen-
ted in Table 6). A cut-off score of 19 for MoCA turned
out to be comparable to a cut-off of 27 for MMSE. 
The MoCA test showed no advantage over MMSE in
dementia detection. 
During MCI versus controls comparison, MoCA
cut-off scores of 25 or 26 were characterized by good
sensitivity with false negative rates of 11.9 and 9.5%,
respectively. However, there were quite high false posi-
tive ratios, namely 69.5 and 62.16%. The optimum cut-
off based on an ROC curve analysis, with best positive
and negative likelihood ratios, proved to be 24 (results
are presented in Table 7). As the false positive rate still
equals 46%, the MoCA test may not be considered an
ideal tool to discriminate MCI from healthy elderly;
nevertheless, it is still considerably better than the
MMSE in terms of sensitivity (compare with Table 5). 
In conclusion, we propose to employ the MoCA cut-
off score of 24 to screen for MCI and a cut-off score of
19 to detect dementia with optimal precision.
There were no detectable differences in terms of dia-
gnosing AD when using either test, with a slight ten-
dency towards superiority of the MoCA (difference of
area under the curve [AUC] 0.05; 95% CI: 0.02 to
0.13; p = 0.14). In terms of detecting MCI, the diffe-
rence between the tests was greater, though again it did
not reach statistical significance (difference of AUC
0.13; 95% CI: 0.01 to 0.26; p = 0.08). However, as 
the AUC for detecting MCI using the MMSE was dri-
Test and cut-off Sensitivity Specificity + Likelihood – Likelihood Number needed
score used Ratio Ratio to diagnose
MoCA ≤ 17 62.9 (44.9-78.5) 92.4 (84.2-97.1) 8.3 0.4 1.8
MoCA ≤ 18 77.1 (59.9-89.5) 86.1 (76.4-92.8) 5.5 0.3 1.6
MoCA ≤ 19* 85.7 (69.7-95.1) 82.3 (72.1-90.0) 4.8 0.2 1.5
MoCA ≤ 20 91.4 (76.9-98.1) 72.1 (60.9-81.7) 3.3 0.1 1.6
MoCA ≤ 21 94.3 (80.8-99.1) 64.6 (53.0-75.0) 2.7 0.1 1.7
Table 6. Psychometric characteristics of the Montreal Cognitive Assessment (MoCA) test in differentiating patients with dementia (N = 36) from controls or individu-
als with mild cognitive impairment (MCI) (N = 79). Optimum cut-off based on ROC curve with area under the curve (AUC) 0.91 (95% CI: 0.85-9.6) equalled 
19 and is marked with an asterisk
Test and cut-off Sensitivity Specificity + Likelihood – Likelihood Number needed
score used Ratio Ratio to diagnose
MoCA ≤ 22 54.8 (38.7-70.1) 67.6 (50.2-82.0) 1.7 0.7 4.5
MoCA ≤ 23 71.4 (55.4-84.3) 62.2 (44.8-77.5) 1. 9 0.5 3.0
MoCA ≤ 24* 80.9 (65.9-91.4) 54.0 (36.9-70.5) 1.8 0.3 2.9
MoCA ≤ 25 88.1 (74.4-96.0) 40.5 (24.8-57.9) 1.5 0.3 3.5
MoCA ≤ 26 90.5 (77.4-97.3) 37.8 (22.5-55.2) 1.5 0.2 3.5
Table 7. Psychometric characteristics of the Montreal Cognitive Assessment (MoCA) test in differentiating patients with mild cognitive impairment (MCI) (N = 42) from
controls (N = 37). Optimum cut-off based on ROC curve with area under the curve (AUC) 0.74 (95% CI: 0.63-0.83) equalled 24 and is marked with an asterisk
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ven mostly by specificity and for MoCA by sensitivity,
the latter test seems to be a better option when screening
for MCI. This assumption, however, needs further vali-
dation.
Discussion
The MMSE remains the most frequently used cogni-
tive screening instrument. It is appreciated as the best tool
for ruling out a diagnosis of dementia in the community
and primary care. However, its sensitivity to detect early
AD and, in particular, MCI cases is inadequate [29]. In
our study, the commonly recommended MMSE cut-off
score for diagnosing dementia (24 points) yielded a high-
ly unacceptable result of 40% false negatives (for the
Polish version of the MMSE). The best parameters in
terms of likelihood ratios and false negative results were
achieved with a cut-off score of 26.
The MoCA test seems to be an ideal tool for dia-
gnosing suspected MCI cases, sensitive for individu-
als performing well on MMSE, resistant to educatio-
nal bias. Nasreddine et al. compared the psychometric
properties of the MMSE and MoCA in the original
paper and reported high sensitivity and specificity for
detecting MCI, as currently conceptualized, in patients
performing in the normal range on MMSE [7]. Using
a cut-off score of 26, the MMSE had a sensitivity of
18% to detect MCI, whereas the MoCA correctly attri-
buted 90% of MCI subjects. The analysis of mild AD
cases demonstrated a sensitivity of 78%, whereas MoCA
detected 100% of cases. Specificity was excellent for
both the MMSE and MoCA (100% and 87%, respec-
tively).
Our preliminary data [25], consistently with fin-
dings of others [15,30], proved that lowering the cut-
off score from the originally proposed 26 to 24 points
significantly improved test accuracy. The use of the
MoCA cut-off score of 26 showed good sensitivity of
detecting cognitively impaired subjects (0.94 [95% CI:
0.87-0.98]), but with unacceptably low specificity (0.35
[95% CI: 0.2-0.44]). Overall accuracy of the test was
found to equal 0.76 (95% CI: 0.66-0.82). On the other
hand, when a cut-off score of 24 was selected, the test
performance in correctly detecting cognitively impaired
subjects improved significantly. Sensitivity declined mar-
ginally compared with the original 26-point threshold
(0.90 [95% CI: 0.82-0.96]) while specificity was incre-
ased to 0.65 (95% CI: 0.48-0.78), providing an overall
accuracy of 0.81 (95% CI: 0.7-0.89). 
In the current study, we found MMSE to perform
poorly in discriminating MCI versus normal controls.
False negative screening for MCI was as high as 52.5%
even for MMSE ≤ 27, while using MMSE ≤ 28 gave
an unacceptable 59.5% rate of false positives.
As mentioned above, the MoCA seems to perform
better in this area, but the ideal cut-off threshold is open
to debate. Luis et al. showed that using the recommen-
ded cut-off score of 26, the MoCA detected 97% of
cognitively impaired subjects but specificity was fair
(35%) [15]. Lowering the cut-off score to 23 excellen-
tly improved sensitivity (96%) and specificity (95%) 
of the MoCA test. In our study, MoCA cut-off scores
of 25 or 26 were characterized by good sensitivity, with
false negative rates of 11.9 and 9.5%, respectively.
However, there were quite high false positive rates of
69.5 and 62.16%, respectively. The optimum cut-off
based on an ROC curve analysis proved to be 24. The Po -
lish version of the MoCA test performed marginally bet-
ter than the MMSE in discriminating MCI from con-
trols (but not reaching statistical significance; p = 0.08).
The detection of MCI using the MMSE was driven
mostly by specificity (72.9 for 27 points) and for the
MoCA by sensitivity (80.9 for 24 points), making the
latter test a better choice when screening for MCI. It
can be explained by the low number of subjects partici-
pating in our study. Smith et al. studied a comparable
number of cases, reporting MMSE and MoCA sensi-
tivities comparable to the study by Nasreddine; how-
ever, specificity of the test was significantly lower (50%
vs. 87%) [30]. 
Several methodological issues limit the interpretation
of the results of this study. Firstly, the diagnosis relied
solely on the clinical picture, without pathological con-
firmation. Secondly, a limited number of cases were inc-
luded in this study. Due to the low number of studied
subjects, assumptions on the utility of the MoCA as com-
pared to the MMSE should be interpreted with caution.
The cut-off thresholds should be verified in some inde-
pendent samples. Thirdly, during preparation of the
Polish version of the MoCA test, some problems arose.
As mentioned above, the scale was adapted through
translation and back translation to guarantee semantic
equivalence. The Polish version of the MoCA is identi-
cal to the English version. We decided to replace two
sentences used in the repetition task with their Polish
equivalents carrying the same meaning. The second
obstacle while preparing the Polish adaptation was the
need to modify the letter fluency item (compare with the
Spanish version) [31]. The letter F is used as part of 
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the MoCA in many other (non-English-speaking) coun-
tries [7,32,33]. As mentioned above, the choice of let-
ters depends on their relative frequencies in different lan-
guages; however, normative data are available for these
versions. For example, letters K, S, P or M and W are
used in Polish in routine clinical practice but the nor-
malization of this variant is still lacking. Moreover, 
these letters are used for research purposes and publica-
tions alongside the ‘FAS’ version. The standardization
of the test is essential as – in the absence of normative
data – clinicians may administer many alternative ver-
sions. In this study, the importance of the letter F for the
interpretation of results is marginal (1 point per 30 points
for the complete test). Those arguments supported 
the use of the letter F in our version of the test. How-
ever, because of rational doubts regarding its use, other
variants of the Polish MoCA test (employing alternati-
ve letters) are planned. Finally, there were some doubts
considering the choice of words for the learning task. We
decided to use the list of words directly from the English
version, translated into Polish for the guaranteed seman-
tic equivalence. The same strategy was chosen by many
authors of other European versions of the MoCA (ava-
ilable at www.mocatest.org). Further studies with modi-
fied variants of the MoCA test are planned.
The differences in age and education level between
the compared groups were significant, which could
potentially bias analyses of diagnostic efficacy. To mini-
mize this risk, mathematical adjustments were introdu-
ced allowing the evaluation of the MoCA and MMSE
scales independently of the confounding variables.
The main applicability of the study is the finding that
the Polish version of the MoCA can be used in every-
day clinical practice in a Polish population for the detec-
tion of cognitive impairment.
We have demonstrated that the Polish versions of the
MMSE and MoCA tests are comparable in discrimi-
nating mild dementia from both MCI and control gro-
ups. Further research is required to reliably determine
sensitivity and specificity of the MoCA test, and its abi-
lity to discriminate MCI from normal cognitive func-
tioning should be validated in longitudinal studies.
Conclusions
1. The Polish versions of the MMSE and MoCA tests
are comparable in discriminating mild dementia from
both MCI and control groups.
2. We propose to apply the MoCA test for MCI scre-
ening using an optimal cut-off score of 24 and for
dementia detection using a cut-off score of 19. The cut-
off thresholds should be verified in other independent
samples.
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